Kestra Medical (KMTS) Director Corrects Purchase; Awarded 10,909 RSUs

Rhea-AI Filing Summary

Raymond W. Cohen, a director of Kestra Medical Technologies, Ltd. (KMTS), reported two equity transactions. He purchased 17,000 common shares at $17.00 on 03/07/2025 that were reserved under the issuer's IPO reserved share program and were inadvertently omitted from earlier filings. He also received 10,909 restricted stock units (RSUs) on 09/04/2025; each RSU converts into one common share and the RSUs vest on 09/04/2026 subject to continued service. The report shows 29,994 shares beneficially owned after the March purchase and 40,903 shares beneficially owned following the RSU grant.

Positive

• Corrective disclosure of previously omitted IPO-reserved share purchase improves transparency
• Director ownership increased to 40,903 shares, aligning executive and shareholder interests
• RSUs with one-year vesting incentivize continued service

Negative

• Prior omission of IPO-reserved share purchase required corrective filing
• No performance-based vesting disclosed for RSUs (time-based only)

Insights

Financial Analyst

TL;DR: Insider purchased shares and received RSUs, modestly increasing direct ownership to 40,903 shares.

The March purchase of 17,000 shares at $17 appears to rectify a prior reporting omission tied to the IPO reserved share program, while the September award is a standard RSU grant vesting in one year. Both actions increase the director's direct stake and align his interests with shareholders. These are routine insider transactions that do not, on their own, signal a material change to company fundamentals.

Corporate Governance Expert

TL;DR: Transactions are governance-standard: corrective disclosure of an omission and a time‑based RSU grant with typical vesting condition.

The Form 4 discloses a corrective purchase entry and a restricted stock unit grant subject to continued service through vesting. The corrective disclosure is important for compliance and transparency. The RSU vesting schedule is time-based with no performance conditions disclosed. From a governance perspective, these items reflect routine director compensation and reporting remediation rather than governance changes.

Insider Trade Summary

Net Buyer: 17,000 shares ($289,000)

Net Buy 2 txns

Insider COHEN RAYMOND W

Role Director

Bought 17,000 shs ($289K)

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	10,909	$0.00	--
Purchase	Common Shares	17,000	$17.00	$289K

Holdings After Transaction: Common Shares — 40,903 shares (Direct)

Footnotes (1)

1. The reported securities in this row were purchased in connection with the Issuer's initial public offering reserved share program and were inadvertently omitted from the Reporting Person's prior filings. The reported securities in this row represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COHEN RAYMOND W

(Last) (First) (Middle)

C/O KESTRA MEDICAL TECHNOLOGIES, LTD.

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WA 98033

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/07/2025		P		17,000(1)	A	$17	29,994	D
Common Shares	09/04/2025		A		10,909(2)	A	(2)	40,903	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported securities in this row were purchased in connection with the Issuer's initial public offering reserved share program and were inadvertently omitted from the Reporting Person's prior filings.

2. The reported securities in this row represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date.

	/s/ Traci S. Umberger as attorney-in-fact for Raymond W. Cohen	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Raymond W. Cohen report for KMTS?

He purchased 17,000 common shares at $17.00 on 03/07/2025 and was granted 10,909 RSUs on 09/04/2025.

How many shares does Raymond W. Cohen beneficially own after the reported transactions (KMTS)?

The filing reports 29,994 shares after the March purchase and 40,903 shares following the RSU grant.

When do the RSUs reported by Raymond W. Cohen vest?

The 10,909 RSUs vest on 09/04/2026, subject to the reporting person’s continued service.

Why was a purchase disclosed as a corrective item in the Form 4 for KMTS?

The filing states the 17,000-share purchase was reserved under the issuer’s IPO reserved share program and was inadvertently omitted from prior filings.

Are there derivative securities reported for Raymond W. Cohen in this Form 4?

No derivative securities (options, warrants, convertible instruments) are reported in Table II of the Form 4.